105 related articles for article (PubMed ID: 24680060)
21. The protease of human T-cell leukemia virus type-1 is a potential therapeutic target.
Tözsér J; Weber IT
Curr Pharm Des; 2007; 13(12):1285-94. PubMed ID: 17504236
[TBL] [Abstract][Full Text] [Related]
22. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease.
Kádas J; Weber IT; Bagossi P; Miklóssy G; Boross P; Oroszlan S; Tözsér J
J Biol Chem; 2004 Jun; 279(26):27148-57. PubMed ID: 15102858
[TBL] [Abstract][Full Text] [Related]
23. Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1.
Yang W; Lu W; Lu Y; Zhong M; Sun J; Thomas AE; Wilkinson JM; Fucini RV; Lam M; Randal M; Shi XP; Jacobs JW; McDowell RS; Gordon EM; Ballinger MD
J Med Chem; 2006 Feb; 49(3):839-42. PubMed ID: 16451048
[TBL] [Abstract][Full Text] [Related]
24. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors.
Nguyen JT; Zhang M; Kumada HO; Itami A; Nishiyama K; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2008 Jan; 18(1):366-70. PubMed ID: 18006315
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting HTLV-1 Protease: A Viable Antiviral Target.
Lockbaum GJ; Henes M; Talledge N; Rusere LN; Kosovrasti K; Nalivaika EA; Somasundaran M; Ali A; Mansky LM; Kurt Yilmaz N; Schiffer CA
ACS Chem Biol; 2021 Mar; 16(3):529-538. PubMed ID: 33619959
[TBL] [Abstract][Full Text] [Related]
26. Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents.
Truong AP; Probst GD; Aquino J; Fang L; Brogley L; Sealy JM; Hom RK; Tucker JA; John V; Tung JS; Pleiss MA; Konradi AW; Sham HL; Dappen MS; Tóth G; Yao N; Brecht E; Pan H; Artis DR; Ruslim L; Bova MP; Sinha S; Yednock TA; Zmolek W; Quinn KP; Sauer JM
Bioorg Med Chem Lett; 2010 Aug; 20(16):4789-94. PubMed ID: 20634069
[TBL] [Abstract][Full Text] [Related]
27. C-terminal residues of mature human T-lymphotropic virus type 1 protease are critical for dimerization and catalytic activity.
Kádas J; Boross P; Weber IT; Bagossi P; Matúz K; Tözsér J
Biochem J; 2008 Dec; 416(3):357-64. PubMed ID: 18636969
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: prime side chromane-containing inhibitors.
Ng RA; Sun M; Bowers S; Hom RK; Probst GD; John V; Fang LY; Maillard M; Gailunas A; Brogley L; Neitz RJ; Tung JS; Pleiss MA; Konradi AW; Sham HL; Dappen MS; Adler M; Yao N; Zmolek W; Nakamura D; Quinn KP; Sauer JM; Bova MP; Ruslim L; Artis DR; Yednock TA
Bioorg Med Chem Lett; 2013 Aug; 23(16):4674-9. PubMed ID: 23856050
[TBL] [Abstract][Full Text] [Related]
29. Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design.
Li M; Laco GS; Jaskolski M; Rozycki J; Alexandratos J; Wlodawer A; Gustchina A
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18332-7. PubMed ID: 16352712
[TBL] [Abstract][Full Text] [Related]
30. Solid-phase synthesis of HTLV-1 protease inhibitors containing hydroxyethylamine dipeptide isostere.
Akaji K; Teruya K; Aimoto S
J Org Chem; 2003 Jun; 68(12):4755-63. PubMed ID: 12790579
[TBL] [Abstract][Full Text] [Related]
31. Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent.
Charrier N; Clarke B; Demont E; Dingwall C; Dunsdon R; Hawkins J; Hubbard J; Hussain I; Maile G; Matico R; Mosley J; Naylor A; O'Brien A; Redshaw S; Rowland P; Soleil V; Smith KJ; Sweitzer S; Theobald P; Vesey D; Walter DS; Wayne G
Bioorg Med Chem Lett; 2009 Jul; 19(13):3669-73. PubMed ID: 19477642
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of potent beta-secretase inhibitors containing a hydroxyethylamine dipeptide isostere and their structure-activity relationship studies.
Tamamura H; Kato T; Otaka A; Fujii N
Org Biomol Chem; 2003 Jul; 1(14):2468-73. PubMed ID: 12956063
[TBL] [Abstract][Full Text] [Related]
33. Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics.
Charrier N; Clarke B; Cutler L; Demont E; Dingwall C; Dunsdon R; Hawkins J; Howes C; Hubbard J; Hussain I; Maile G; Matico R; Mosley J; Naylor A; O'Brien A; Redshaw S; Rowland P; Soleil V; Smith KJ; Sweitzer S; Theobald P; Vesey D; Walter DS; Wayne G
Bioorg Med Chem Lett; 2009 Jul; 19(13):3674-8. PubMed ID: 19406640
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles.
Nguyen JT; Kato K; Hidaka K; Kumada HO; Kimura T; Kiso Y
Bioorg Med Chem Lett; 2011 Apr; 21(8):2425-9. PubMed ID: 21392990
[TBL] [Abstract][Full Text] [Related]
35. Maintaining potent HTLV-I protease inhibition without the P3-cap moiety in small tetrapeptidic inhibitors.
Nguyen JT; Kato K; Kumada HO; Hidaka K; Kimura T; Kiso Y
Bioorg Med Chem Lett; 2011 Mar; 21(6):1832-7. PubMed ID: 21316958
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.
Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 May; 16(10):5795-802. PubMed ID: 18400502
[TBL] [Abstract][Full Text] [Related]
37. Identification of the RT-RH/IN cleavage site of HTLV-I.
Mariani VL; Shuker SB
Biochem Biophys Res Commun; 2003 Jan; 300(2):268-70. PubMed ID: 12504078
[TBL] [Abstract][Full Text] [Related]
38. Molecular insights of protein contour recognition with ligand pharmacophoric sites through combinatorial library design and MD simulation in validating HTLV-1 PR inhibitors.
Selvaraj C; Omer A; Singh P; Singh SK
Mol Biosyst; 2015 Jan; 11(1):178-89. PubMed ID: 25335799
[TBL] [Abstract][Full Text] [Related]
39. Comparative study of the unbinding process of some HTLV-1 protease inhibitors using unbiased molecular dynamics simulations.
Tiyoula FN; Aryapour H; Moghadam MJ
PLoS One; 2022; 17(7):e0263200. PubMed ID: 35834445
[TBL] [Abstract][Full Text] [Related]
40. Efficient expression and rapid purification of human T-cell leukemia virus type 1 protease.
Ding YS; Owen SM; Lal RB; Ikeda RA
J Virol; 1998 Apr; 72(4):3383-6. PubMed ID: 9525666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
